Engineered for the Clinical Race

Talem Therapeutics takes antibody discovery and development to the next level.

Gain access to a vault of next-generation, fully-human antibodies to streamline your path to the clinic.

Premium Programs

High-value targets

Talem preclinical experts match high value targets to fully vetted, premium antibody programs. Catapult your discovery project past the launch phase and accelerate to clinical success. Select from key targets for multiple indications, for licensing or co-development, including:

• Discovery, preclinical and IND-enabling antibody programs

• A broad range of indications: immuno-oncology, oncology, COVID-19, ophthalmology, inflammation, immunology, and infectious, rare/neglected, autoimmune, and heart diseases

The PolyTope® Advantage

Talem has been actively involved in SARS-CoV-2 research since January 2020. One of its most advanced development programs, TATX-03 (anti-SARS-CoV-2 PolyTope® antibody cocktail), is a rationally designed, fully human, 4-antibody cocktail containing potently neutralizing antibodies against non-overlapping epitopes on SARS-CoV-2. Talem’s SARS-CoV-2 PolyTope® therapy is designed to reduce mutagenic escape risk with an emphasis on efficacy for every patient, variant, and strain of SARS-CoV-2, and has been developed with the goal of sustainable efficacy as the virus evolves, combining broadly characterized, neutralizing and synergistic antibodies that exhibit diverse epitope coverage.

> Polytope® TATX-03 Additional Information

Contact Us

For Business Development Opportunities

The expertise at Talem is the culmination of 30 years of combined experience, thousands of programs, greater than 600 clients worldwide (including 80% of the top 20 pharmaceutical companies) and a unique HUB of intelligence to guide you to the clinic.

For more information contact us:

info@ipatherapeutics.com

One Broadway, 14th floor
Cambridge, MA 02142, USA

For Investor Inquiries
investors@ipatherapeutics.com

ImmunoPrecise Antibodies
ipatherapeutics.com